An Overview of Lenacapavir for PrEP Trials

Embed Download PDF Download Image

The PURPOSE trials evaluate the safety and efficacy of injectable lenacapavir (LEN), an investigational antiretroviral (ARV) drug being studied as a potential PrEP product. This graphic shows the latest status of all five trials including the groundbreaking results of PURPOSE 1. Read more here.

Accelerating Product Innovation
Tracking and Translating the Field